Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636038 | 1.00 | PDE4B (0.48) | PDE4BLDHASIGMAR1CA12CA1 | |
| SCHEMBL18324158 | 0.87 | PDE4B (0.48) | PDE4BLDHASIGMAR1L3MBTL1ADRB2 | |
| SCHEMBL16929911 | 0.80 | SIGMAR1 (0.55) | PDE4BLDHASIGMAR1CA2L3MBTL1 | |
| SCHEMBL4456615 | 0.78 | L3MBTL1 (0.47) | PDE4BLDHACA12CA1CA2 | |
| SCHEMBL28323447 | 0.78 | LDHA (0.60) | LDHASIGMAR1L3MBTL1HTR2AMAPK1 | |
| SCHEMBL17287644 | 0.77 | SIGMAR1 (0.47) | PDE4BLDHASIGMAR1L3MBTL1KDM4E | |
| SCHEMBL20608395 | 0.77 | SIGMAR1 (0.50) | PDE4BLDHASIGMAR1L3MBTL1MAPK1 | |
| SCHEMBL10325870 | 0.75 | PTGS2 (0.54) | PDE4BCA12CA1CA2CA5A | |
| SCHEMBL17287712 | 0.75 | SIGMAR1 (0.45) | PDE4BLDHASIGMAR1L3MBTL1KDM4E | |
| SCHEMBL5304491 | 0.75 | CALM1 (0.55) | KDM4EMAPTCALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341359-B1 | PROCESS FOR PREPARATION OF APREMILAST | GLENMARK LIFE SCIENCES LTD (IN) | 2022-03-23 | — | — | EP | claimed |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | AMGEN INC. (US) | 2022-03-01 | — | — | US | claimed |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | AMGEN INC. | 2021-01-28 | — | — | US | claimed |
| US-20180134660-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | MYLAN LABORATORIES LIMITED (IN) | 2018-05-17 | — | — | US | claimed |
| EP-2420490-B1 | Method for the preparation of (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORP (US) | 2016-07-20 | — | — | EP | claimed |
| EP-2420490-A1 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | claimed |
| EP-2651400-B2 | CONTROLLED RELEASE ORAL DOSAGE FORMS OF POORLY SOLUBLE DRUGS AND USES THEREOF | AMGEN EUROPE GMBH (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3341359-B1 | PROCESS FOR PREPARATION OF APREMILAST | GLENMARK LIFE SCIENCES LTD (IN) | 2022-03-23 | — | — | EP | disclosed |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | AMGEN INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-11040024-B2 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | AMGEN INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3320902-B1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | AMGEN EUROPE GMBH (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-10919855-B2 | Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide | UNICHEM LABORATORIES LTD (IN) | 2021-02-16 | — | — | US | disclosed |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | AMGEN INC. | 2021-01-28 | — | — | US | disclosed |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | MAN HON-WAH | 2004-07-29 | — | — | US | disclosed |
| US-6667316-B1 | Amido or imido functionality; tumor necrosis factor alpha, phosphodiesterases, matrix metalloproteases and angiogenesis inhibitors | CELGENE CORPORATION | 2003-12-23 | — | — | US | disclosed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003080048-A1 | (-)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
| EP-1228071-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1228071-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034606-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134660-A1 | PROCESS FOR THE ENANTIOMERIC RESOLUTION OF APREMILAST INTERMEDIATES | QDPR, TPMT, DNPEP | PDE4B 1826/4885LDHA 1764/4885SIGMAR1 695/4885 |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | PDE4A, PDE2A, PDE3A | PDE4B 6/4885LDHA 2526/4885SIGMAR1 619/4885 |
| US-11040024-B2 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | PDE4A, PDE2A, PDE4B | PDE4B 3/4885LDHA 2556/4885SIGMAR1 442/4885 |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | PDE4A, PDE4B, PDE2A | PDE4B 2/4885LDHA 2874/4885SIGMAR1 469/4885 |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | PDE3A, PDE5A, PDE2A | PDE4B 14/4885LDHA 2993/4885SIGMAR1 675/4885 |
| US-10919855-B2 | Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide | DMPK, BCKDK, MYLK | PDE4B 905/4885LDHA 1858/4885SIGMAR1 2056/4885 |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | PDE4A, PDE4B, PDE2A | PDE4B 2/4885LDHA 2874/4885SIGMAR1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.